Navigation Links
Isolagen, Inc. Submits Biologics License Application for the Treatment of Wrinkles to the U.S. Food and Drug Administration
Date:3/9/2009

tial financing alternatives and potential strategic partnership discussions. However, there can be no assurance that any such potential financing alternative will be completed on terms acceptable to the Company, or successfully completed at all. Further, there can be no assurance that any potential strategic partnership discussions will be completed on terms acceptable to the Company, or completed at all. If the Company does not obtain additional funding, or anticipate additional funding in the very near future, the Company may enter into bankruptcy, and possibly cease operations. In addition, as previously disclosed, the Company currently has a debt liability of approximately $89.7 million related to its 3.5% subordinated notes, which could be called due, at the option of the note holders, as early as November 2009. Interest on the notes is due semiannually on May 1 and November 1.

Further, the Company is pursuing the potential sale of its 57% ownership interest in Agera Laboratories, Inc. There can be no assurance that a sale of this ownership interest will be completed on terms acceptable to the Company, or successfully completed at all.

About Isolagen, Inc.

Isolagen(TM), Inc. (Amex: ILE) is an aesthetic and therapeutic company committed to developing and commercializing scientific advances and innovative technologies. The company's technology platform includes the Isolagen Process(TM), a cell processing system for skin and tissue rejuvenation which is currently in clinical development for a broad range of aesthetic and therapeutic applications including wrinkles, acne scars, burns and periodontal disease. Isolagen also commercializes a scientifically-advanced line of skincare systems through its majority-owned subsidiary, Agera(R) Laboratories, Inc. For additional information, please visit

SOURCE Isolagen, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant
2. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
3. Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study
4. Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents
5. ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410
6. Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children
7. U.S. Naval Medical Research Center Resubmits IND Application for Proposed Op RESUS Clinical Trial in Trauma Patients in the Battlefield Setting
8. Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
9. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
10. U.S. Navy Submits Protocol for Field Trauma Trial of Hemopure(R)
11. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015 Microbrush International, a leading ... in dental restorative procedures, today announced the acquisition ... an innovative sectional matrix system used in dental ... about the opportunity to add DentiSmart to our ... Frymark , VP and General Manager of Microbrush. ...
(Date:5/4/2015)... 4, 2015  The board of directors of Eli Lilly ... for the second quarter of 2015 of $0.50 per share ... payable June 10, 2015, to shareholders of record at the ... Lilly and Company Lilly is a global healthcare leader that ... around the world. We were founded more than a century ...
(Date:5/4/2015)... -- PAREXEL International Corporation (NASDAQ: PRXL ) announced today ... on Monday, May 18, 2015, in New York City.  ... will be making a presentation on PAREXEL and discussing business ... of the presentation will be available through the "Investors" section ... Events portion of the main page, and a replay of ...
Breaking Medicine Technology:Microbrush International Announces Acquisition of DentiSmart 2PAREXEL International to Present at UBS Healthcare Conference 2
... , Strategic collaboration with Ipsen for marketing rights ... and the US , Photocure to commercialise the ... ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic ... a new commercial strategy for Hexvix, its flagship product  to ...
... FRANCISCO, Calif., Sept. 26, 2011 diaDexus, Inc. (OTC ... focused on the development and commercialization of patent-protected in ... today announced the Board of Directors, appointment of a ... a new chief business officer, R. Michael Richey. Dr. ...
Cached Medicine Technology:Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 2Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 3Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 4Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 5Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 6Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 7Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 8diaDexus Appoints New CEO Brian E. Ward, Ph.D. and New CBO Michael Richey 2diaDexus Appoints New CEO Brian E. Ward, Ph.D. and New CBO Michael Richey 3diaDexus Appoints New CEO Brian E. Ward, Ph.D. and New CBO Michael Richey 4diaDexus Appoints New CEO Brian E. Ward, Ph.D. and New CBO Michael Richey 5
(Date:5/4/2015)... (PRWEB) May 04, 2015 The ... Gregs G. Thomopulos, P.E., Chairman of Stanley Consultants ... (ISI) board of directors for a three-year term. , ... (APWA) and the American Society of Civil Engineers (ASCE). ... sustainability rating system for civil infrastructure called Envision. Launched ...
(Date:5/4/2015)... HHT is a rare but cruel and ... can have seemingly mild symptoms like frequent nosebleeds, it ... Hemorrhagic Telangiectasia (HHT) is a hereditary disorder resulting in ... connections between an artery and a vein. These abnormalities ... may also be present in the lungs, brain and ...
(Date:5/4/2015)... May 04, 2015 The University ... today launched a new initiative at UC Davis ... generation of physicians committed to advancing Latino health. ... Medicos, or Preparing Students to Be Physicians, (“Prep ... will provide scholarships, mentorship and internship opportunities, a ...
(Date:5/4/2015)... Each year, the Susan G. Komen organization hosts 5K ... breast cancer. This year, Dr. Mark Deutsch and his staff ... sponsor for the 25th annual Susan G. Komen Greater Atlanta ... Square Mall. , The Komen organization hopes have 10,000 participants ... Perimeter Plastic Surgery has not only taken on the role ...
(Date:5/4/2015)... 2015 Johnson & Wales University (JWU) held ... science academic center on Wednesday, April 22. , Johnson & ... made available by the re-alignment of Interstate-195. JWU’s new academic ... and Chestnut streets in Providence, is scheduled to be completed ... of land the university purchased in 2012. , “It has ...
Breaking Medicine News(10 mins):Health News:Thomopulos Appointed to Institute for Sustainable Infrastructure Board 2Health News:Frequent Nosebleeds Can Be a Sign of a Rare Undiagnosed Disease - Cure HHT 2Health News:Frequent Nosebleeds Can Be a Sign of a Rare Undiagnosed Disease - Cure HHT 3Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 2Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 3Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 4Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 5Health News:Perimeter Plastic Surgery Sponsors 2015 Susan G. Komen Greater Atlanta "Race for the Cure" 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 3
... . The death rate from injuries ... urban areas, according to a new study by researchers ... Center for Injury Research and Policy. Rural males of ... from injuries than urban males, and the overall rate ...
... SCOTTSDALE, Ariz., and LONDON, Ontario Jan. 12, 2010 ... Inc. (COTI) (TSXV:COT) announced today that they will work ... promising new anti-cancer drug called COTI-2. This easily ... COTI of London, Ontario, Canada. This working relationship resulted ...
... , ... from the bimonthly biomedical journal, Molecular Medicine. Molecular Medicine publishes research concerned with the ... for disease diagnosis, treatment and prevention. , ... (Vocus) January 12, 2010 -- By the time a person ...
... , , NASHVILLE, Tenn. , Jan. ... provider of healthcare revenue and payment cycle management solutions, today announced that ... Healthcare Services Conference to be held from January 25 to 27, ... Tracy Bahl , Executive Chairman, will begin at 11:45 a.m. Eastern ...
... cuts that risk significantly, study finds , TUESDAY, Jan. 12 ... increase in resting heart rate boosts the risk of dying ... has found. , Norwegian researchers tracked the health of about ... of 18 years. During that time, 6,033 men and 4,442 ...
... ... participate in SharpBrains Summit without taking a single flight , ... San Francisco, CA (PRWEB) ... fitness, today announced the inaugural SharpBrains Summit, the first global and virtual conference ...
Cached Medicine News:Health News:Significant urban-rural disparities in injury mortality seen in China 2Health News:TD2 and Critical Outcome Technologies Inc. develop novel anti-cancer drug 2Health News:TD2 and Critical Outcome Technologies Inc. develop novel anti-cancer drug 3Health News:News from the Latest Issue of Molecular Medicine 2Health News:Emdeon to Present at the Jefferies Global Healthcare Services Conference 2Health News:Faster Heart Rate May Raise Risk of Heart Attack Death 2Health News:First Global, Virtual Summit on Cognitive Health and Performance Features 200 Sharp Brains 2Health News:First Global, Virtual Summit on Cognitive Health and Performance Features 200 Sharp Brains 3Health News:First Global, Virtual Summit on Cognitive Health and Performance Features 200 Sharp Brains 4
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
... Eppendorf Reference Series 2000 Pipette is a ... a compact and robust design, and superior ... used to operate the measuring stroke and ... Product features:Eppendorf "pipette/tip" system ensures utmost accuracy ...
500L...
... fixed pipette is ideal for ... volume. Fixed volume FInnpipettes offer ... as other Finnpipette Digital pipettes: ... blow-out (1-40ul), Soft-touch tip ejection, ...
Medicine Products: